Skip to main content
. 2021 Dec 8;14:427–440. doi: 10.2147/IJNRD.S331484

Figure 2.

Figure 2

Serum and urine NGAL levels in HIV+ CKD patients and Controls (A and C) and HIV+ CKD histological types (B and D). Horizontal lines within each box indicate median values with the boxes extending from the 25th to the 75th percentile. Whiskers denote values within 1.5 x IQR, and dots indicate outlier values outside this range. p-values for each graph calculated comparing all participants (A and C) or all HIV-positive CKD patients (B and D) using the Kruskal–Wallis test with post-hoc analysis performed pairwise using Dunn’s Multiple Comparison Test. Significant associations: (A) HIV+ CKD vs HIV+ no-CKD p=0.031; HIV+ CKD vs healthy controls p<0.001; HIV+ no-CKD vs healthy controls p=0.016. (B) HIVAN vs MCD p=0.004; HIVAN vs HIV-ICD p=0.035. (C) HIV+ CKD vs healthy controls p=0.002; HIV+ no-CKD vs healthy controls p=0.026. (D) HIVAN vs MCD p=0.006.

Abbreviations: CKD, chronic kidney disease; FSGS, Focal segmental glomerulosclerosis; HIVAN, HIV-associated nephropathy; HIV-ICD, HIV immune complex disease; IQR, Interquartile range; MCD, minimal change disease; NGAL, neutrophil gelatinase-associated lipocalin.